Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Take action
Record your position on this measure.
Create an account to record your position, submit testimony, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Overview
This bill, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, would allow Medicare to cover and pay for multi-cancer early detection screening tests starting in 2028. These tests, which must be FDA-cleared or approved and analyze multiple cancer types, would be limited to individuals under age 68 in 2028 (increasing annually) and would be performed every 11 months. The bill also establishes payment amounts and standards for these screenings, with adjustments over time.
Key provisions
- Medicare coverage and payment for multi-cancer early detection screening tests starting in 2028.
- Tests must be FDA-cleared or approved and analyze multiple cancer types.
- Coverage is limited to individuals under age 68 in 2028, increasing annually.
- Tests can only be performed every 11 months.
- Payment amounts are established, with adjustments over time, referencing existing stool screening DNA tests.
- The Secretary uses the National Coverage Determination (NCD) process for new test coverage.
- Exemptions for tests recommended with an ‘A’ or ‘B’ grade by the US Preventive Services Task Force.
- The bill does not affect coverage for other cancer screening tests like breast, cervical, colorectal, lung, or prostate cancer.
Who is affected
- Medicare beneficiaries
- Healthcare providers offering multi-cancer early detection screening tests
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
251 on record
Primary sponsor
Cosponsors
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours